Home » Stocks » URGN

UroGen Pharma Ltd. (URGN)

Stock Price: $22.76 USD 0.64 (2.89%)
Updated Jan 26, 2021 9:33 AM EST - Market open
Market Cap 464.23M
Revenue (ttm) 3.83M
Net Income (ttm) -136.93M
Shares Out 22.06M
EPS (ttm) -6.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $22.76
Previous Close $22.12
Change ($) 0.64
Change (%) 2.89%
Day's Open -
Day's Range 21.88 - 22.76
Day's Volume 6,015
52-Week Range 13.68 - 31.28

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Business Wire - 1 week ago

PRINCETON, N.J. & HOUSTON--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancer...

Seeking Alpha - 2 weeks ago

UroGen's Jelmyto, approved April 2020 for LG-UTUC, has a J code effective 1/1/2021 allowing for dramatically more convenient coding & reimbursement. Revenues should be about $115,000/patient a...

Business Wire - 2 weeks ago

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urolo...

Business Wire - 1 month ago

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urol...

Business Wire - 1 month ago

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN) a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urolo...

Business Wire - 2 months ago

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN) today announced final topline results from the single-arm, open-label OPTIMA II Phase 2b trial evaluating the efficacy and s...

Business Wire - 2 months ago

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urol...

Business Wire - 2 months ago

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urolo...

Seeking Alpha - 2 months ago

UroGen Pharma's (URGN) CEO Liz Barrett on Q3 2020 Results - Earnings Call Transcript

Benzinga - 2 months ago

Shares of UroGen Pharma (NASDAQ:URGN) were unchanged after the company reported Q3 results.

Business Wire - 2 months ago

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urol...

Business Wire - 2 months ago

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq: URGN), a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urol...

Business Wire - 3 months ago

NEW YORK--(BUSINESS WIRE)--UroGen Pharma Ltd. (Nasdaq:URGN), a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases because patien...

Business Wire - 4 months ago

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd.

Business Wire - 4 months ago

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd.

Business Wire - 4 months ago

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd.

Seeking Alpha - 5 months ago

Oncology Stocks Area Trading Materially Lower The Last 2 Months

Other stocks mentioned: BYSI, GTHX, KPTI
Seeking Alpha - 5 months ago

Of a pool of 26 oncology stocks we track, with 1 exception, all (literally 25 of 26) are trading materially lower from the third week of June 2020.

Other stocks mentioned: BYSI, GTHX, KPTI
Seeking Alpha - 5 months ago

UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q2 2020 Results - Earnings Call Transcript

Business Wire - 5 months ago

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd.

Business Wire - 5 months ago

PRINCETON, N.J.--(BUSINESS WIRE)--UroGen Pharma Ltd.

Seeking Alpha - 8 months ago

UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q1 2020 Results - Earnings Call Transcript

Seeking Alpha - 8 months ago

UroGen Is A Compelling Value With Recent FDA Approval

InvestorPlace - 8 months ago

Whether or not a recovery is imminent, there are compelling stocks to buy, it’s just a matter of where you look for them.

Other stocks mentioned: AMRC, CATM, EHTH, GWPH, HCA, QSR
Market Watch - 9 months ago

Shares of UroGen Pharma Ltd. gained 10.7% in premarket trading on Thursday after the Food and Drug Administration approved the company's urothelial cancer treatment the night before.

Zacks Investment Research - 9 months ago

UroGen (URGN) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Seeking Alpha - 10 months ago

UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q4 2019 Results - Earnings Call Transcript

Seeking Alpha - 1 year ago

UroGen Pharma Ltd. (URGN) CEO Elizabeth Barrett on Q3 2019 Results - Earnings Call Transcript

The Motley Fool - 1 year ago

Investors walked away from UroGen Pharma after an article was published by a short-seller, but clinical results appear to favor the company.

Seeking Alpha - 1 year ago

UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q2 2019 Results - Earnings Call Transcript

The Motley Fool - 1 year ago

Should you follow in their footsteps?

Other stocks mentioned: CTL, ECA
The Motley Fool - 1 year ago

A major milestone gets closer with each passing day, but the stock seems to keep heading lower.

Zacks Investment Research - 1 year ago

UroGen Pharma Ltd. (URGN) has been struggling lately, but the selling pressure may be coming to an end soon.

The Motley Fool - 1 year ago

Wall Street, and most investors who follow its lead, is overlooking this online bank, pharmaceutical company, and master limited partnership. Investors who are paying attention could score out...

Other stocks mentioned: ALLY, NBLX
The Motley Fool - 1 year ago

Axsome Therapeutics, Flexion Therapeutics, and UroGen Pharma gave investors reasons for excitement.

Other stocks mentioned: AXSM, FLXN
Seeking Alpha - 1 year ago

UroGen Pharma Ltd. (URGN) CEO Liz Barrett on Q1 2019 Results - Earnings Call Transcript

The Motley Fool - 1 year ago

This Canadian midstream company, Canadian winter clothing manufacturer, and Israel-based pharma company could soon be making names for themselves in the U.S.

Other stocks mentioned: GOOS, PBA
The Motley Fool - 1 year ago

This Israeli-based pharma company is poised to receive regulatory approval for its first product in the second half of 2019.

About URGN

UroGen Pharma, a clinical stage biopharmaceutical company, focuses on developing solutions for specialty cancers and urologic diseases. The company's lead product candidates are UGN-101 and UGN-102, which are designed to ablate tumors by non-surgical means and to treat several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial carcinoma and low-grade non-muscle invasive bladder cancer. It is also developing UGN-201, a proprietary immunotherapy product candidate for the treatment of high-grade non-muscle... [Read more...]

Industry
Biotechnology
IPO Date
May 4, 2017
CEO
Elizabeth Barrett
Employees
187
Stock Exchange
NASDAQ
Ticker Symbol
URGN
Full Company Profile

Financial Performance

In 2019, UroGen Pharma's revenue was $18,000, a decrease of -98.40% compared to the previous year's $1.13 million. Losses were -$105.15 million, 39.0% more than in 2018.

Financial Statements

Analyst Forecasts

According to 8 analysts, the average rating for UroGen Pharma stock is "Buy." The 12-month stock price forecast is 41.00, which is an increase of 80.14% from the latest price.

Price Target
$41.00
(80.14% upside)
Analyst Consensus: Buy